## Amendments to the Claims:

- 1-57. (canceled)
- 58. (canceled)
- 59. (canceled)
- 60. (canceled)
- 61. (currently amended) An isolated polypeptide of Claim 58 comprising a polypeptide sequence having at least 95% amino acid sequence identity to:
  - (a) the amino acid sequence of the polypeptide of SEQ ID NO:523;
  - (b) the amino acid sequence of the polypeptide of SEQ ID NO:523, lacking its associated signal peptide; or
  - [[(c)]] (b) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209487, wherein said polypeptide induces chondrocyte re-differentiation.
- 62. (currently amended) An isolated polypeptide of Claim [[58]] 61 comprising a polypeptide sequence having at least 99% amino acid sequence identity to:
  - (a) the amino acid sequence of the polypeptide of SEQ ID NO:523;
  - (b) the amino acid sequence of the polypeptide of SEQ ID NO:523, lacking its associated signal peptide; or
  - (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209487, wherein said polypeptide induces chondrocyte re-differentiation.
  - 63. (previously presented) An isolated polypeptide comprising:
  - (a) the amino acid sequence of the polypeptide of SEQ ID NO:523;
  - (b) the amino acid sequence of the polypeptide of SEQ ID NO:523, lacking its associated signal peptide; or
  - (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209487.

- 64. (currently amended) The isolated polypeptide of Claim 63 comprising the amino acid sequence of the polypeptide of SEQ ID NO:523.
- 65. (currently amended) The isolated polypeptide of Claim 63 comprising the amino acid sequence of the polypeptide of SEQ ID NO:523, lacking its associated signal peptide.
  - 66. (canceled)
  - 67. (canceled)
- 68. (previously presented) The isolated polypeptide of Claim 63 comprising the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209487.
- 69. (currently amended) A chimeric polypeptide comprising a polypeptide according to Claim 58 or 71 61 or 74 fused to a heterologous polypeptide.
- 70. (previously presented) The chimeric polypeptide of Claim 69, wherein said heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin.
  - 71. (canceled)
  - 72. (canceled)
  - 73. (canceled)
- 74. (currently amended) An isolated polypeptide of Claim 71 comprising a polypeptide sequence having at least 95% amino acid sequence identity to:
  - (a) the amino acid sequence of the polypeptide of SEQ ID NO:523;
  - (b) the amino acid sequence of the polypeptide of SEQ ID NO:523, lacking its associated signal peptide; or
  - [[(c)]] (b) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209487, wherein said polypeptide induces proliferation of rat utricular supporting cells.

- 75. (currently amended) An isolated polypeptide of Claim [[71]] 74 comprising a polypeptide sequence having at least 99% amino acid sequence identity to:
  - (a) the amino acid sequence of the polypeptide of SEQ ID NO:523;
  - (b) the amino acid sequence of the polypeptide of SEQ ID NO:523, lacking its associated signal peptide; or
  - (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209487, wherein said polypeptide induces proliferation of rat utricular supporting cells.